Chloroquine

Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers

Friday, March 27, 2020 - 3:01pm

Hydroxychloroquine is a medication used for the prevention and treatment of certain types of malaria, as well as rheumatoid arthritis, lupus, and porphyria cutanea tarda.

Key Points: 
  • Hydroxychloroquine is a medication used for the prevention and treatment of certain types of malaria, as well as rheumatoid arthritis, lupus, and porphyria cutanea tarda.
  • In non-human studies, researchers have identified two medicines, chloroquine and hydroxychloroquine, as having activity against SARS-coronaviruses.
  • Rising Pharmaceuticals -- and its partner Laurus Labs Limited in Hyderabad, India -- manufacture Hydroxychloroquine Sulphate, USP Tablets under an FDA approved drug application.
  • Vimal Kavuru, CEO of Rising Pharmaceuticals said, We started talking to the University of Minnesota just over a week ago and have fast tracked our efforts to support this critically needed study.

The Cardiac Risk of Chloroquine in Unapproved Indications

Friday, March 27, 2020 - 1:57am

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.

Innoplexus Announces Major Findings in Potential Combination Therapies for COVID-19

Thursday, March 26, 2020 - 8:32pm

However, Hydroxychloroquine is a potential and immediately available treatment cost-effective option, although it could have major side effects for specific patient groups.

Key Points: 
  • However, Hydroxychloroquine is a potential and immediately available treatment cost-effective option, although it could have major side effects for specific patient groups.
  • Additionally, Innoplexus' AI evaluated the clinical potential of medications approved for other diseases to identify promising drug combinations that work synergistically to interrupt disease mechanisms.
  • These findings suggest that a combination of Hydroxychloroquine or Chloroquine with several previously approved drugs might yield better results than any drug administered alone.
  • Finally, Innoplexus has also generated potential candidates for novel molecules using its deep generative models powered by NVIDIA's DGX-1 supercomputers.

March 26 Statement: Lupus Research Alliance Puts Plaquenil Shortage Into Perspective For Lupus Community

Thursday, March 26, 2020 - 1:07pm

Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.

Key Points: 
  • Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.
  • The Lupus Research Alliance will continue to monitor the situation closely and push for continued access for people with lupus while working to ensure shortages abate in the future.
  • More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.

Medical Experts Explain the Use and Potential Adverse Effects of Chloroquine & Hydroxychloroquine for COVID-19

Wednesday, March 25, 2020 - 12:45am

PHOENIX, March 24, 2020 /PRNewswire-PRWeb/ -- Several medications are being evaluated in studies or are being used off-label to treat COVID-19 infections.

Key Points: 
  • PHOENIX, March 24, 2020 /PRNewswire-PRWeb/ -- Several medications are being evaluated in studies or are being used off-label to treat COVID-19 infections.
  • In response to several recent poisonings and one death associated with the use of chloroquine to treat COVID-19, the American College of Medical Toxicology (ACMT) is offering this free webinar "Medical & Public Health Considerations of Chloroquine & Hydroxychloroquine Use during the COVID-19 Pandemic" on Wednesday March 25, 2020 at 3pm EDT.
  • Join this briefing to learn from leading medical toxicologists, experts in the care of poisoned patients, as they discuss the use of, and potential adverse effects with, these drugs as physicians consider these therapies to treat patients with COVID-19.
  • The webinar will be moderated by Dr. Paul Wax, ACMT Executive Director, and presented by Dr. Ziad Kazzi, ACMT Board Member and MENATOX President.

Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection

Tuesday, March 24, 2020 - 12:00pm

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection.
  • ADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, drugs currently in clinical testing for the treatment of COVID-19 infection.
  • Reproxalap has also demonstrated preliminary activity in a preclinical model of ARDS3.
  • Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue.

Vizient Offers Recommendation to Coronavirus Task Force and FDA to Improve Hospitals’ Access to Chloroquine and Hydroxychloroquine as Suppliers Unable to Keep Up with 6,842% and 2,196% Increases in Orders

Tuesday, March 24, 2020 - 10:00am

Over the last week, we have seen 6,842% and 2,196% increase in orders by Vizient members for chloroquine and hydroxychloroquine, respectively, since the World Health Organization declared COVID-19 a pandemic.

Key Points: 
  • Over the last week, we have seen 6,842% and 2,196% increase in orders by Vizient members for chloroquine and hydroxychloroquine, respectively, since the World Health Organization declared COVID-19 a pandemic.
  • Any new suppliers coming to market or donating large inventory of products should request that the distributors prioritize health systems.
  • All other distribution of chloroquine and hydroxychloroquine should be directed to the hospital/acute care environment where critically ill patients with COVID-19 are managed.
  • Vizient has earned a Worlds Most Ethical Company designation from the Ethisphere Institute every year since its inception.

The Quinism Foundation Calls on State Boards of Pharmacy to Enact Uniform Restrictions to Limit Hoarding of Quinoline Antimalarial Drugs Against COVID-19

Monday, March 23, 2020 - 11:00pm

WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.

Key Points: 
  • WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.
  • [1,2] "However, the same common properties that likely underlie the effectiveness of these quinoline antimalarial drugs against the virus may also underlie their common dangers."
  • "While hydroxychloroquine is among the safest drugs of the quinoline antimalarial class, all antimalarial quinolines share a common toxicity," said Dr. Nevin.
  • Dr. Nevin also emphasized that the Quinism Foundation has recently called on Congress to fund research into chronic quinoline encephalopathy.

Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus

Thursday, March 19, 2020 - 4:31pm

Bayer today announced it is joining the U.S. Government's fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate).

Key Points: 
  • Bayer today announced it is joining the U.S. Government's fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate).
  • Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the bodys immune response.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.

Chinese Scientist Unite Together to Tackle With COVID-19

Tuesday, February 18, 2020 - 5:08pm

Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.

Key Points: 
  • Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.
  • As a consequence, they discovered potentially effective anti- coronavirus drugs, such as Chloroquine Phosphate, Remdesivir, and Favipiravir.
  • "The positive curative effect has been shown in treating COVID-19," said Zhang Boli, the project leader and the headmaster of Tianjin University of Traditional Chinese Medicine.
  • Several new type of vaccines for COVID-19 have started the animal testing phase, which bring hope to all.